During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic ...

New research in the July 2025 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated ...

Bengaluru: Prostate cancer remains one of the most frequently diagnosed malignancies among men worldwide, including in India.

The FDA granted fast track designation to TRE-515 plus radioligand therapy for treating PSMA-positive metastatic ...

An expert discusses how radiopharmaceuticals such as radium-223 offer a valuable different mechanism of action in treating advanced prostate cancer, requiring careful patient selection, safety ...

The tissue damage and anatomical distortion caused by primary prostate cancer treatment are major challenges for surgeons performing salvage surgery.

Men with non-metastatic forms are likely to live 'for many years' after diagnosis when active surveillance and other NCCN ...

ArteraAI Prostate analyzes digital pathology images of a prostate cancer biopsy slide to help clinicians predict long-term outcomes.

Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic ...

Prostate cancer focal therapies include cryotherapy, irreversible electroporation ablation (IRE), & high-intensity focused ultrasound (HIFU).

Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate ...

“Personalizing treatment in this way may lessen harmful side effects, reduce damage to healthy cells and make it more likely ...